Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INO
  • CUSIP:
Key Metrics:
  • Previous Close: $8.86
  • 50 Day Moving Average: $9.15
  • 200 Day Moving Average: $9.03
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.32
  • P/E Growth: 0.00
  • Market Cap: $651.64M
  • Outstanding Shares: 73,548,000
  • Beta: 2.63
Additional Links:
Companies Related to Inovio Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $18.33 (106.92% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetDetails
8/18/2016Maxim GroupReiterated RatingHoldView Rating Details
8/13/2016HC WainwrightReiterated RatingBuy$17.00View Rating Details
8/8/2016Brean CapitalSet Price TargetBuy$18.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingOverweight$31.00View Rating Details
7/17/2016Stifel NicolausReiterated RatingBuy$13.00View Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.19)($0.18)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
DateHeadline
News IconInovio Expands Ebola Vaccine Trial (NASDAQ:INO)
jutiagroup.com - August 25 at 10:39 AM
News IconInovio Expands Ebola Vaccine Trial INO (NASDAQ:INO)
www.investorideas.com - August 25 at 10:39 AM
News IconInovio Pharmaceuticals, Inc. (INO) - Strategic and Financial SWOT Analysis Review (NASDAQ:INO)
emailwire.com - August 24 at 5:31 PM
News IconInteresting INO Put And Call Options For October 21st (NASDAQ:INO)
www.stockoptionschannel.com - August 23 at 10:01 AM
investornewswire.com logoWill Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Hit $31 Price Target? - Investor Newswire (NASDAQ:INO)
www.investornewswire.com - August 22 at 10:14 AM
fool.com logo3 Reasons Inovio Pharmaceuticals Inc. Stock Could Rise -- The ... - Motley Fool (NASDAQ:INO)
www.fool.com - August 20 at 9:51 AM
News IconHC Stocks Overview: Inovio Pharmaceuticals Inc (NASDAQ:INO), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NASDAQ:INO)
sharemarketupdates.com - August 18 at 5:42 PM
News IconInovio Pharma licenses veterinary vaccine for FMD to Plumbline Life Sciences (NASDAQ:INO)
pharmabiz.com - August 18 at 8:39 AM
bizjournals.com logoInovio licenses experimental veterinary vaccine to South Korean firm (NASDAQ:INO)
www.bizjournals.com - August 18 at 8:39 AM
4-traders.com logoInovio Pharmaceuticals : Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences (NASDAQ:INO)
www.4-traders.com - August 18 at 8:39 AM
News IconBetter Buy: Novavax, Inc. vs. Inovio Pharmaceuticals - Madison.com (NASDAQ:INO)
host.madison.com - August 17 at 5:51 PM
finance.yahoo.com logoINOVIO PHARMACEUTICALS, INC. Financials (NASDAQ:INO)
finance.yahoo.com - August 16 at 5:49 PM
finance.yahoo.com logo8:03 am Inovio Pharma licenses a veterinary vaccine for foot and mouth disease to Plumbline Life Sciences, co in South Korea (NASDAQ:INO)
finance.yahoo.com - August 16 at 12:03 PM
publicnow.com logoInovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences (NASDAQ:INO)
www.publicnow.com - August 16 at 12:03 PM
capitalcube.com logoETF’s with exposure to Inovio Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:INO)
www.capitalcube.com - August 15 at 3:29 PM
finance.yahoo.com logoInovio Expands Enrollment in Ebola Vaccine Phase I Study (NASDAQ:INO)
finance.yahoo.com - August 15 at 3:29 PM
finance.yahoo.com logoObama Moves Money Around To Keep Zika Research Going Amid Lack Of Congressional Funds Allocation (NASDAQ:INO)
finance.yahoo.com - August 12 at 5:43 PM
smarteranalyst.com logoWhat HC Wainwright Thinks of Inovio Pharmaceuticals Inc (INO) Following 2Q Results - Smarter Analyst (NASDAQ:INO)
www.smarteranalyst.com - August 12 at 8:50 AM
smarteranalyst.com logoMaxim Comments on Inovio Pharmaceuticals Inc (INO) as Ebola Vaccine Study Expands - Smarter Analyst (NASDAQ:INO)
www.smarteranalyst.com - August 12 at 8:50 AM
smarteranalyst.com logoThe Biotech Round-Up: Valeant Pharmaceuticals Intl Inc (VRX), Inovio Pharmaceuticals Inc (INO), Synergy ... - Smarter Analyst (NASDAQ:INO)
www.smarteranalyst.com - August 11 at 5:55 PM
fool.com logoBetter Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation -- The ... - Motley Fool (NASDAQ:INO)
www.fool.com - August 11 at 5:55 PM
reuters.com logoBRIEF-Inovio expands positive Phase I Ebola vaccine trial (NASDAQ:INO)
www.reuters.com - August 11 at 8:40 AM
publicnow.com logoInovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen (NASDAQ:INO)
www.publicnow.com - August 11 at 8:39 AM
capitalcube.com logoInovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:INO)
www.capitalcube.com - August 10 at 5:55 PM
fortune.com logoAnalyst Views To Note: Inovio Pharmaceuticals Inc (NASDAQ:INO), Rayonier Advanced Materials Inc (NYSE:RYAM) - Review Fortune (NASDAQ:INO)
reviewfortune.com - August 10 at 8:34 AM
barrons.com logoInovio Pharma May Be Burning Too Hot - Barron's (NASDAQ:INO)
www.barrons.com - August 10 at 8:34 AM
News IconNews Fact on Vanguard Level- Fluor (NYSE:FLR), Inovio Pharmaceuticals (NASDAQ:INO), Graphic Packaging (NYSE ... - Seneca Globe (NASDAQ:INO)
www.senecaglobe.com - August 9 at 5:50 PM
News IconIntegrated Device Technology (NASDAQ:IDTI) & Inovio Pharmaceuticals (NASDAQ:INO) Stocks Intraday Alert - Money News (press release) (NASDAQ:INO)
www.newsismoney.com - August 9 at 5:50 PM
equities.com logoInovio Pharmaceuticals Inc. (INO) Drops 5.08% on August 08 - Equities.com (NASDAQ:INO)
www.equities.com - August 9 at 5:50 PM
thecountrycaller.com logoZika Threat: GlaxoSmithKline plc (GSK), Inovio Pharmaceuticals Inc (INO), Sanofi SA (SNY); What Are The Options - TCC (NASDAQ:INO)
www.thecountrycaller.com - August 9 at 5:50 PM
benzinga.com logoInovio Pharma Shares Higher As Q2 Sales Beat (NASDAQ:INO)
www.benzinga.com - August 9 at 8:40 AM
finance.yahoo.com logoGeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine (NASDAQ:INO)
finance.yahoo.com - August 9 at 8:40 AM
investornewswire.com logoStrong Sell Calls For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) At 0 - Investor Newswire (NASDAQ:INO)
www.investornewswire.com - August 8 at 5:51 PM
News IconHC Stocks in Hub: Inovio Pharmaceuticals Inc (NASDAQ:INO ... - share market updates (press release) (NASDAQ:INO)
sharemarketupdates.com - August 8 at 5:51 PM
benzinga.com logoInovio Pharma Shares Higher As Q2 Sales Beat - Benzinga (NASDAQ:INO)
www.benzinga.com - August 8 at 5:51 PM
thestreet.com logoInovio (INO) Stock Slumps After Mixed Q2 Results (NASDAQ:INO)
www.thestreet.com - August 8 at 5:51 PM
News IconInovio Pharma appoints Dr Ami Shah Brown as vice president regulatory affairs (NASDAQ:INO)
www.pharmabiz.com - August 8 at 10:21 AM
rttnews.com logoEARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q2 Earnings Report (NASDAQ:INO)
www.rttnews.com - August 8 at 10:21 AM
reuters.com logoBRIEF-Inovio Pharmaceuticals Q2 loss per share $0.26 (NASDAQ:INO)
www.reuters.com - August 8 at 10:21 AM
sg.finance.yahoo.com logoInovio reports 2Q loss (NASDAQ:INO)
sg.finance.yahoo.com - August 8 at 10:21 AM
publicnow.com logoInovio Pharmaceuticals Reports 2016 Second Quarter Financial Results (NASDAQ:INO)
www.publicnow.com - August 8 at 10:21 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Companhia de Saneamento Basico do Estado de Sao Paulo, Cemig, iShares MSCI Brazil ETF and Inovio Pharmaceuticals (NASDAQ:INO)
finance.yahoo.com - August 8 at 10:21 AM
finance.yahoo.com logoInovio (INO) Reports In-Line Loss in Q2, Revenues Beat (NASDAQ:INO)
finance.yahoo.com - August 8 at 10:21 AM
globenewswire.com logoInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs - GlobeNewswire (press release) (NASDAQ:INO)
globenewswire.com - August 5 at 8:42 AM
equities.com logoInovio Pharmaceuticals Inc. (INO) Drops 5.51% on August 03 - Equities.com (NASDAQ:INO)
www.equities.com - August 5 at 8:42 AM
reuters.com logoBRIEF-Inovio Pharmaceuticals appoints Ami Shah Brown as VP regulatory affairs - Reuters (NASDAQ:INO)
www.reuters.com - August 4 at 5:59 PM
capitalcube.com logoETF’s with exposure to Inovio Pharmaceuticals, Inc. : August 4, 2016 (NASDAQ:INO)
www.capitalcube.com - August 4 at 5:59 PM
finance.yahoo.com logoInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs - Yahoo Finance (NASDAQ:INO)
finance.yahoo.com - August 4 at 8:39 AM
News IconInovio Pharmaceuticals and Roche Holding Part Ways in Immunotherapy Molecule Development - Business Finance News (NASDAQ:INO)
www.businessfinancenews.com - August 4 at 8:39 AM
publicnow.com logoInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs (NASDAQ:INO)
www.publicnow.com - August 4 at 8:39 AM

Social

Inovio Pharmaceuticals (NASDAQ:INO) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff